Regeneron Pharmaceuticals, Inc. (BMV:REGN)

Mexico flag Mexico · Delayed Price · Currency is MXN
9,485.00
0.00 (0.00%)
At close: Jun 5, 2025, 2:00 PM CST
-46.09%
Market Cap 978.36B
Revenue (ttm) 287.90B
Net Income (ttm) 91.96B
Shares Out n/a
EPS (ttm) 805.86
PE Ratio 10.64
Forward PE 12.67
Dividend 35.03 (0.37%)
Ex-Dividend Date May 20, 2025
Volume n/a
Average Volume 66
Open 9,485.00
Previous Close 9,485.00
Day's Range 9,485.00 - 9,485.00
52-Week Range 9,485.00 - 23,707.11
Beta n/a
RSI 4.42
Earnings Date Aug 1, 2025

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]

Industry Pharmaceutical Preparations
Founded 1988
Employees 15,106
Stock Exchange Mexican Stock Exchange
Ticker Symbol REGN
Full Company Profile

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD Financial Statements

News

There is no news available yet.